Verastem, a pre-clinical stage biotech developing stem cell therapies for metastatic cancers, raised $55 million by offering 5.5 million shares at $10, the midpoint of the range of $9 to $11. Verastem plans to list on the NASDAQ under the symbol VSTM. UBS Investment Bank and Leerink Swann acted as lead managers on the deal.
